Shares of Amarin (NASDAQ:AMRN) tumbled over 67% in the first six months of the year, according to data provided by S&P Global Market Intelligence. The stock slid from the beginning of the year through most of the first quarter, but the precipitous drop was the result of an unfavorable ruling on the company's intellectual property at the end of March.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,